The financial performance of H. Lundbeck A/S in 2021 was negatively affected by the loss of patent protection for Northera, a key neurology drug. Despite this, the company is forecasting a rebound in 2022 on demand for Vyepti, a recently launched medicine for migraine prevention. Group sales in 2021 were DKK 16.3 billion ($2.5 billion), down by 8% from a year earlier following a 74% decline in revenue for Northera. Northera, a drug for neurogenic orthostatic hypotension, lost exclusivity in February 2021.
